Main Uses and Therapeutic Areas

АЦЦ 100 is a mucolytic agent primarily used to facilitate the removal of thick, viscous mucus from the respiratory tract. It is indicated for the treatment of respiratory conditions characterized by the formation of excessive or overly dense bronchial secretions.

Common clinical applications include:

• Acute Bronchitis: Assisting in the clearance of mucus during sudden-onset inflammation of the bronchial tubes.
• Chronic Bronchitis: Managing long-term airway inflammation where persistent mucus production is a factor.
• Tracheitis and Laryngotracheitis: Addressing inflammation of the trachea and larynx that results in phlegm buildup.
• Bronchiectasis: Supporting airway hygiene in conditions where the bronchial tubes are permanently widened and prone to mucus accumulation.

Mechanism and Benefits

The primary therapeutic benefit of АЦЦ 100 is its ability to alter the physical properties of mucus. By breaking the chemical bonds (disulfide bridges) within the mucopolysaccharides of the phlegm, the medication reduces its viscosity.

Key benefits of this action include:

• Improved Expectoration: Thinner mucus is more easily transported by the ciliary epithelium and expelled through coughing.
• Respiratory Relief: Reducing the accumulation of secretions helps to maintain airway patency and may decrease the intensity of productive coughs.
• Supportive Action in Infections: By promoting the drainage of secretions, it helps minimize the environment where bacteria can proliferate, assisting the body's natural recovery processes in the respiratory system.

Regulatory References

1. NIH MedlinePlus guidance

Official Eligibility Profile for ACC 100 (Acetylcysteine)

This section outlines the eligibility and non-eligibility criteria for oral acetylcysteine (ACC 100) based strictly on authoritative government regulatory labeling.

Contraindications (Who Must Not Use)

Classification	Population/Condition
Absolute Contraindication	Hypersensitivity to acetylcysteine or any excipient.
Absolute Contraindication	Children under 2 years of age.
Absolute Contraindication	Patients with active peptic ulceration.
Absolute Contraindication	Hereditary metabolic disorders (e.g., fructose intolerance, galactose malabsorption) due to excipient content.

Restricted or Conditional Use (Special Caution)

Use of ACC 100 is generally allowed for adults and children aged 2 years and older who do not have the contraindications listed above. However, special caution is required for certain populations:

• Patients with Asthma: Use requires caution due to the potential to provoke bronchospasm.
• Patients with a History of Peptic Ulcer: Caution is advised, especially when used with other gastrointestinal irritants.
• Pregnancy and Lactation: Use is not recommended or should be avoided unless clearly necessary, due to insufficient data establishing safety in these populations. The patient's physician must assess the benefit against potential risks.

Interactions with other medicines and products

Official government regulatory documents describe several clinically significant interaction patterns for Acetylcysteine, primarily focused on pharmacodynamic effects and chemical incompatibilities. There are no formally designated contraindicated combinations listed in major regulatory labeling.

Documented Pharmacodynamic Interactions

Interacting Substance	Official Interaction Pattern
Cough Suppressants (Antitussives)	Antagonistic interaction; co-administration may lead to the dangerous accumulation of bronchial secretions due to the suppression of the cough reflex.
Nitrates (e.g., Nitroglycerin)	Synergistic effect; co-administration may potentiate the vasodilating actions of nitrates, potentially resulting in clinically significant hypotension (low blood pressure).

Chemical and Pharmacokinetic Restrictions

Administration of oral antibiotics (including Tetracyclines, Aminoglycosides, and Cephalosporins) must be separated from Acetylcysteine by an interval of at least two hours. This mandatory timing rule is required to prevent a direct chemical inactivation of the antibiotic compound, ensuring its therapeutic effect. The regulatory profile also notes that Acetylcysteine may lead to a reduced plasma concentration of Carbamazepine. Furthermore, the co-administration of Activated Charcoal may diminish the therapeutic effect of Acetylcysteine through chemical adsorption. There are no mandatory warnings regarding interactions with food, alcohol, or common herbal products documented in the regulatory interaction section.

Direct Chemical Liquefaction (Secretolysis)

This domain covers the primary method by which Acetylcysteine acts upon the respiratory secretions. The molecule's free thiol group (–SH) directly attacks and cleaves the disulfide bonds (S-S) that link the polymeric mucoprotein complexes, initiating a process called secretolysis. This chemical reduction breaks down the sticky, rigid structure of the mucins, resulting in a rapid reduction in viscosity and elasticity.

---

Facilitating Muco-ciliary Clearance

This block details the resulting physiological effect of the primary chemical action. The transformation of highly viscous secretions into a liquid state physically enables the transport of mucus by the body’s own muco-ciliary apparatus. The mechanism acts by modulating the physical state of the secretions, thereby facilitating the function of the clearance mechanisms.

---

️ Secondary Antioxidant Support

This secondary mechanism involves the drug's role as a precursor to L-cysteine, which is the rate-limiting substrate for the synthesis of the critical endogenous antioxidant, Glutathione (GSH). The increase in GSH stores supports the endogenous management of oxidative stress in the respiratory tract.

---

️ Mechanistic Constraints

The drug's primary secretolytic mechanism is physiologically constrained, as it is highly dependent on the presence of disulfide-bonded mucoproteins. The primary secretolytic mechanism exhibits reduced activity on secretions that are thin or derived primarily from non-mucoprotein components. Furthermore, the mechanism does not modulate ciliary motor function; therefore, the resulting effect on the transport of the liquefied secretions may be reduced if the ciliated epithelium is compromised.

Official Administration Guidelines

АЦЦ 100 (Acetylcysteine 100 mg) is primarily designated for oral administration, typically provided as effervescent tablets or granules intended for dissolution. There is a specific protocol for preparation, dosing, and timing.

---

Dosing and Frequency

The dosage regimens are defined by age group, with the 100 mg strength commonly aligned with pediatric use. Dosing recommendations are categorized as follows:

• Children 2 to 7 years: The total daily dose is 200 mg, which is often divided and administered as 100 mg taken twice daily. The maximum recommended daily intake for this age group is 400 mg.
• Children <2 years: Prescribing information may advise a total daily intake of 100 mg to 150 mg, often divided into 50 mg doses, but use in this population requires specific caution due to reduced expectoration capacity.
• Adults/Adolescents (> 7 years): While higher strengths (e.g., 200 mg or 600 mg) are commonly used, the total daily intake is generally 600 mg, divided across two or three daily administrations.

---

Preparation and Timing Constraints

The oral form must be properly prepared prior to ingestion:

• Preparation: The effervescent tablet or powder must be fully dissolved in a small glass of water immediately before consumption. The entire resulting solution should be consumed right away.
• Course Duration: For acute conditions, use is generally limited to a short-term course, such as 8 to 10 days. Therapy for chronic conditions may require long-term use under the direction of a physician.
• Special Timing: Due to the substance's possible chelating effect, the oral intake of Acetylcysteine must be separated by at least 2 hours from the administration of medicines or supplements containing salts of gold, calcium, or iron. Effectiveness is not dependent on timing relative to meals.

Research evidence / Overview of studies

Overview of Core Efficacy Studies

The research summary focuses on clinical findings from trials involving АЦЦ 100 (acetylcysteine). Studies have investigated whether the drug may be associated with improvements in clinical outcomes and changes in pain levels. The data primarily comes from randomized, placebo-controlled trials (RCTs) and subsequent meta-analyses.

Several studies have evaluated its use in long-term symptom management. The primary endpoints in these studies focused on changes in a validated symptom severity score (e.g., VAS or NRS) and overall quality of life measures after 12 weeks of treatment.

---

Key Findings from Meta-Analyses

In a large meta-analysis, studies examined whether the drug was associated with a change in symptom severity compared to placebo.

• Symptom Severity: The primary analysis assessed the difference in the mean change in symptom scores between the АЦЦ 100 group and the placebo group.
• Quality of Life: The assessment of long-term quality of life measures yielded varied findings across different publications.
• Duration of Effect: Research has investigated the use of the drug in chronic conditions, with follow-up periods ranging up to one year.

---

Administration Regimens Studied

Research has investigated the use of the drug in specific conditions, but it is not yet clear whether different regimens affect the outcomes.

• Monotherapy: The studies reviewed commonly examined a once-daily regimen. Researchers collected data on symptom changes over time following this regimen in early-phase trials.
• Combination Therapy: Studies have explored whether the combination may be associated with an increase in response rates when АЦЦ 100 is used alongside standard care treatments.

Common questions about АЦЦ 100 (FAQ)

---

Q: Does this medicine make you feel tired or drowsy?

Official product information indicates that drowsiness has been reported as an infrequent adverse effect, most often noted with certain inhalational formulations of the medicine. For the oral forms, this effect is not listed as commonly reported. Product labels contain the full list of safety details.

---

Q: What should I do if I forget to take a dose?

Information on managing a forgotten dose is described in the official instructions for use. It typically describes taking the missed dose upon remembering. It is also described that if it is almost time for the next dose, the missed dose should be skipped to avoid a double dose and to resume the regular schedule.

---

Q: Are there any special considerations for elderly patients?

Regulatory documents do not specifically list problems restricted to the elderly population related to this medicine. However, official sources note that older patients are more likely to have age-related issues with the kidneys, liver, or heart. Any potential adjustments related to age or existing conditions are determined by a physician.

---

Q: What are the inactive ingredients/excipients in the tablet?

The ingredients besides the active substance, known as excipients, can vary based on the specific product formulation (such as powder or effervescent tablet). Common excipients often include certain types of sugars like sucrose, lactose, and sorbitol, as well as sodium. The complete list of ingredients is available on the product label for the specific formulation being used.

---

Q: Is this safe for long-term use (e.g., more than 10 days)?

Official product information defines limits for use in symptomatic treatment. The regulatory recommendation is generally for use not exceeding 8 to 10 days for symptomatic treatment of mucus. Use for chronic conditions is typically addressed under specific clinical guidance.

---

Q: What are the specific indications (uses) for this medicine?

According to official documents, this medicine is indicated as a mucolytic adjuvant (a helpful treatment to thin mucus) for respiratory disorders that involve thick, viscous, excessive mucus. In other contexts, the active ingredient is also approved for use as an antidote for acetaminophen (paracetamol) overdose.

Official Storage and Disposal Instructions for АЦЦ 100 (Acetylcysteine)

Official regulatory documents define strict conditions for storing and disposing of this medication to ensure stability and safety.

Storage Requirement	Official Guideline
Temperature	Store below 25 C (77 F). Do not refrigerate or freeze.
Protection	Protect from light and moisture. The container must be kept tightly closed.
Stability	The dissolved effervescent solution must be used immediately after preparation.
Child Safety	Keep this medicine out of the sight and reach of children.

For disposal, unused or expired АЦЦ 100 must be managed according to local regulatory requirements. The medicine must not be discarded via household waste or wastewater, which helps prevent environmental contamination by the active pharmaceutical ingredient.